Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

BACKGROUND AIMS To evaluate safety and efficacy of FGFR1-3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements (FGFR2F), mutations (FGFR2M), or amplifications (FGFR2A), previously treated with chemotherapy. APPROACH RESULTS Open-label, non-contro...

M. Borad, Michele Droz Dit Busset, M. Javle et al. · 0 citations
Open access Sep 2026

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real‐world study

The objective of this study is to explore and validate a novel prognostic index for patients with locally advanced or metastatic biliary tract cancer (BTC) treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab.

M. Persano, A. Casadei-Gardini, L. Fornaro et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.